Frequent EGFR mutations in brain metastases of lung adenocarcinoma

Frequent EGFR mutations in brain metastases of lung adenocarcinoma
复制标题

DOI:
10.1002/ijc.21940
复制
发表时间:
2006-09-15
影响因子:
6.4
通讯作者:
Yokota, Jun
Yokota, Jun
中科院分区:
医学1区
文献类型:
--
作者:
Matsumoto, Shingo;Takahashi, Kenji;Yokota, Jun

文献摘要

被引文献

相似文献

肺腺癌常发生脑转移,脑转移患者的预后仍然很差。表皮生长因子受体(EGFR)基因突变的原发性肺腺癌的相当一部分,特别是那些与激烈的反应EGFR酪氨酸激酶抑制剂。本研究旨在阐明脑转移瘤中EGFR突变的患病率及其在癌症进展期间发生的时间。EGFR突变在19例肺腺癌脑转移中有12例(63%)。这一频率高于包括日本在内的东亚肺腺癌各阶段EGFR突变的既往研究(即,20-55%)。在6例EGFR突变的病例中,还检查了相应的原发性肺肿瘤的突变,并且在所有这些病例中,在原发性肿瘤中也检测到相同类型的EGFR突变。在其中2例中,除了第一个转移性脑肿瘤外,第二个转移性脑肿瘤也可用于分析,并且在两例病例的第一个和第二个转移性脑肿瘤中均检测到相同类型的EGFR突变。这些结果表明,EGFR突变频繁地存在于脑转移瘤中,并且发生在脑转移瘤之前。这些结果将为脑转移性肺腺癌的治疗提供重要信息。(c)2006 Wiley-Liss,Inc.
Lung adenocarcinomas often metastasize to the brain, and the prognosis of patients with brain metastases is still very poor. The epidermal growth factor receptor (EGFR) gene is mutated in a considerable fraction of primary lung adenocarcinomas, in particular those with drastic response to EGFR tyrosine kinase inhibitors. The present study was designed to elucidate the prevalence of EGFR mutations in brain metastases and the timing of their occurrence during cancer progression. EGFR mutations were detected in 12 of 19 metastatic lung adenocarcinomas to the brain (63%). This frequency was higher than those in previous studies for EGFR mutations at various stages of lung adenocarcinoma in East Asia, including Japan (i.e., 20-55%). In 6 cases with EGFR mutations, the corresponding primary lung tumors were also examined for the mutations, and in all of them, the same types of EGFR mutations were detected also in the primary tumors. In 2 of them, second metastatic brain tumors in addition to the first ones were also available for analysis, and the same types of EGFR mutations were detected in both the first and second ones in both cases. These results indicate that EGFR mutations are present frequently in brain metastases and occur preceding brain metastasis. These findings will be highly informative for treatment of metastatic lung adenocarcinoma io the brain. (c) 2006 Wiley-Liss, Inc.